American clinical stage biopharmaceutical company in South San Francisco, California, founded in 2018 by former Novira and Johnson & Johnson antiviral researchers and listed on Nasdaq. Develops small molecule and oligonucleotide medicines for viral disease and liver disease, with capsid assembly modulators and small interfering RNA programmes for chronic hepatitis B, coronavirus protease inhibitors and a thyroid hormone receptor beta agonist for metabolic liver disease, and runs its own medicinal chemistry, virology and clinical development.
Aucun commentaire disponible.
Laissez votre note & commentaire